Lexicon Pharmaceuticals Profit Margin

The latest profit margin for LXRX is -159.09% as of September 2026. That compares with -96.77% in the prior-year period — down 64.4% year over year. That is below the Healthcare sector average of 19.13%. Investors often review this figure alongside Lexicon Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, LXRX's profit margin moved from -96.77% to -159.09% — a 64.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lexicon Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, LXRX currently prints -159.09% for profit margin, while the sector average sits near 19.13%. That is roughly 931.6% below the sector mean. Large gaps often invite a closer look at Lexicon Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Lexicon Pharmaceuticals converts resources into returns. At -159.09%, LXRX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -96.77% in the prior-year period — down 64.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LXRX's profit margin (-159.09%), review year-over-year change from -96.77%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.